文献速递消化道肿瘤放疗胸部肿瘤放疗

食管癌新辅助放化疗中 elective 淋巴结照射与累及野照射的网络荟萃分析

Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis.
PubMed 文献 · Radiat Oncol · 2019-10-16

结果显示nCRTS-ENI与nCRTS-IFI均显著改善OS,两者在OS、局部复发、远处转移、R0切除及术后死亡率上无显著差异;亚组中nCRTS-IFI对ESCC的OS优势显著,nCRTS-ENI对EAC排名最优。

要点

  • nCRTS-ENI与nCRTS-IFI在OS、局部复发、远处转移、R0切除及术后死亡率上无显著差异。
  • nCRTS-IFI对ESCC的OS显著优于nCTS和手术,nCRTS-ENI未见此优势。
  • nCRTS-ENI采用3D-RT较2D-RT改善OS(HR=0.58,95%CI 0.34-0.99)。

核心结论

  • 采用ENI或IFI的nCRTS均可能是可切除食管癌的最佳治疗,nCRTS-IFI和nCRTS-ENI似乎分别对ESCC和EAC更有效。

研究设计与样本

  • 系统检索PubMed、Embase、Cochrane Library、Web of Science及主要会议,纳入比较nCRTS、nCTS和单纯手术至少两种方案的RCT。

主要发现

  • nCRTS-ENI(HR=0.63,95%CI 0.48-0.83)和nCRTS-IFI(HR=0.75,95%CI 0.66-0.86)均较单纯手术显著改善OS。
  • nCRTS-ENI与nCRTS-IFI在OS、局部复发、远处转移、R0切除及术后死亡率上无显著差异。
  • 亚组分析中nCRTS-IFI对ESCC的OS显著优于nCTS(HR=0.78,95%CI 0.63-0.96)和单纯手术(HR=0.50,95%CI 0.38-0.68),nCRTS-ENI无此优势。
  • nCRTS-ENI采用3D-RT较2D-RT改善OS(HR=0.58,95%CI 0.34-0.99)。
  • OS排名中nCRTS-IFI(0.90)和nCRTS-ENI(0.96)分别为ESCC和EAC的最有效治疗。

关键数值与推荐

  • nCRTS-ENI对比单纯手术OS的HR=0.63(95%CI 0.48-0.83)。
  • nCRTS-IFI对比单纯手术OS的HR=0.75(95%CI 0.66-0.86)。
  • ESCC亚组nCRTS-IFI对比nCTS的OS HR=0.78(95%CI 0.63-0.96),对比单纯手术HR=0.50(95%CI 0.38-0.68)。
  • nCRTS-ENI中3D-RT对比2D-RT的OS HR=0.58(95%CI 0.34-0.99)。
  • OS治疗排名:nCRTS-IFI对ESCC为0.90,nCRTS-ENI对EAC为0.96。

临床怎么用

  • 可切除食管癌行nCRTS时,ENI与IFI在OS及主要安全性指标上无显著差异,均可作为选择。
  • ESCC患者可优先考虑nCRTS-IFI,EAC患者可优先考虑nCRTS-ENI。
  • nCRTS-ENI照射技术宜采用3D-RT而非2D-RT以改善OS。

局限性

  • 结论基于网络荟萃分析,需未来头对头比较试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To assess the comparative efficacy and safety of elective nodal irradiation (ENI) and involved-field irradiation (IFI) in patients with esophageal cancer (EC) receiving neoadjuvant chemoradiotherapy plus surgery (nCRTS). MATERIAL AND METHODS: PubMed, Embase, Cochrane Library, Web of Science and major meetings were searched for randomized controlled trials (RCTs) that compared at least two of the following treatment regimens: nCRTS, neoadjuvant chemotherapy plus surgery (nCTS), and surgery (S) alone. Overall survival (OS) was the primary outcomes of interest, reported as hazard ratio (HR) and 95% confidence intervals (CIs). A Bayesian network meta-analysis was performed to compare all regimens simultaneously. RESULTS: Twenty-nine RCTs with a total of 5212 patients were included in the meta-analysis. Both nCRTS adopting ENI (nCRTS-ENI) (HR = 0.63, 95% CI: 0.48-0.83) and nCRTS adopting IFI (nCRTS-IFI) (HR = 0.75, 95% CI: 0.66-0.86) significantly improved OS compared to S alone. No significant differences in OS, locoregional recurrence, distant metastases, R0 resection and postoperative mortality were observed between nCRTS-ENI and nCRTS-IFI. In subgroup analyses, nCRTS-IFI showed a significant OS advantage over nCTS (HR = 0.78, 95% CI: 0.63-0.96) and S alone (HR = 0.50, 95% CI: 0.38-0.68) for esophagus squamous cell carcinoma (ESCC), but nCRTS-ENI did not; nCRTS-ENI using three-dimensional radiotherapy (3D-RT) resulted in an improved OS compared to that with 2D-RT (HR = 0.58, 95% CI: 0.34-0.99). Based on treatment ranking in term of OS, nCRTS-IFI (0.90) and nCRTS-ENI (0.96) was ranked the most effective treatment for ESCC and esophagus adenocarcinoma (EAC), respectively. CONCLUSION: Either adopting ENI or IFI, nCRTS is likely to be the optimal treatment for resectable EC, and nCRTS-IFI and nCRTS-ENI seem to be more effective for patients with ESCC and EAC, respectively. Future head to head comparison trials are needed to confirm these findings.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liu T, Ding S, Dang J, et al. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. Radiat Oncol. 2019. PMID: 31619265. doi:10.1186/s13014-019-1388-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。